Thomas Stankovich - 04 Jan 2022 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Issuer symbol
RSLS
Transactions as of
04 Jan 2022
Net transactions value
-$5,644
Form type
4
Filing time
28 Jan 2022, 15:46:32 UTC
Previous filing
09 Dec 2021
Next filing
02 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Sale $5,644 -3,171 -0.87% $1.78 362,536 04 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.